Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioiasis ADXBUL:BIOA 12 Return-on-Tangible-Equity is 507.13% as of Sep. 2025, which is 48198% above its 10-year median of 1.05. GuruFocus rates XBUL:BIOA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bioiasis AD's annualized net income for the quarter that ended in Sep. 2025 was €1.03 Mil. Bioiasis AD's average shareholder tangible equity for the quarter that ended in Sep. 2025 was €0.20 Mil. Therefore, Bioiasis AD's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was 507.13%.
The historical rank and industry rank for Bioiasis AD's Return-on-Tangible-Equity or its related term are showing as below:
XBUL:BIOA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -136.93 Med: 1.05 Max: 127.4
Current: 67.5
During the past 13 years, Bioiasis AD's highest Return-on-Tangible-Equity was 127.40%. The lowest was -136.93%. And the median was 1.05%.
XBUL:BIOA's Return-on-Tangible-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 4.855
vs XBUL:BIOA: 67.50
Bioiasis AD (XBUL:BIOA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bioiasis AD Return-on-Tangible-Equity Related Terms
Bioiasis AD Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bioiasis AD's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:BIOA vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Bioiasis AD's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioiasis AD Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioiasis AD's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bioiasis AD's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 507.13% mean?
Bioiasis AD (XBUL:BIOA) has a Return-on-Tangible-Equity of 507.13% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bioiasis AD and its competitors. This is 48198% above median its historical median of 1.05.
Is Bioiasis AD's Return-on-Tangible-Equity too high?
Bioiasis AD's current Return-on-Tangible-Equity of 507.13% is 48198% above median its 10-year median of 1.05. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.86. Bioiasis AD's value of 507.13% is 10345.5% above this industry median. Overall, Bioiasis AD has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioiasis AD's Return-on-Tangible-Equity compare to ABT and SYK?
Bioiasis AD's Return-on-Tangible-Equity of 507.13% can be compared against companies in the Medical Devices & Instruments industry. The industry median Return-on-Tangible-Equity is 4.86. Bioiasis AD's value of 507.13% is 10345.5% above this benchmark. While the company's 10-year median is 1.05 vs. the industry median of 4.86, Bioiasis AD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.86, based on 754 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioiasis AD's current Return-on-Tangible-Equity of 507.13% is 10345.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bioiasis AD and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioiasis AD's current Return-on-Tangible-Equity is 507.13%, which is 48198% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioiasis AD stock overvalued right now?
Bioiasis AD (XBUL:BIOA) has a current Return-on-Tangible-Equity of 507.13%. The current Return-on-Tangible-Equity is 507.13%, which is 48198% above median its 10-year median of 1.05 and 10345.5% above the Medical Devices & Instruments industry median of 4.86. Bioiasis AD's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bioiasis AD (XBUL:BIOA), the current Return-on-Tangible-Equity is 507.13% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioiasis AD provides specialized medical devices, equipment, and consultation services to state and private hospitals and trading companies. The company also deals in Interventional Cardiology and General Surgery consumables.
12GF Score
Get the complete analysis for XBUL:BIOA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:BIOA has been successfully added to your 
